견적문의

NEW YORK--( / )--Philip Morris International (PMI) (NYSE:PM) today announced that its new corporate headquarters will be located in the heart of Stamford, Connecticut, and is expected to open in summer 2022. The move is a notable component of PMI’s transformation to a smoke-free company and?with the support of Gov. Ned Lamont (D) and the company’s leadership?will initially bring approximately 200 jobs to help fuel the state’s continued economic growth. The total economic impact of these jobs is expected to be approximately $50 million in 2022.

“Connecticut’s position as a leader in innovation and forward thinking, paired with a commitment to open-minded civil discourse, allows us to foster an even stronger company culture. PMI will continue to attract an educated workforce, becoming an integral part of the local community and a source of pride for the state,” said Deepak Mishra, President of the Americas Region at PMI.

“We are making rapid progress toward our smoke-free future,” continued Mishra, “and our new base in Connecticut is more than just an office building?it will be a full campus with a state-of-the-art innovation facility that will help accelerate our transformation.” State officials recognize that PMI is a company with a new purpose and bright future. We are proud that we will be able to call Connecticut home.”

The new 71,484 square foot headquarters will be located at 677 Washington Boulevard in the heart of Stamford’s central business district, steps away from the Stamford Transportation Center and the entrance to I-95, making it easily accessible. The office will open as home to the PMI Americas region and other corporate functions. PMI’s Operations Center will remain in Lausanne, Switzerland, to continue to support the business across the globe. The company employs a worldwide workforce of more than 71,000.

“The decision by PMI to locate its corporate headquarters in downtown Stamford is validation that our economic recovery in Connecticut is in full swing, and we are continuing to see meaningful growth in one of our fastest growing cities,” said Governor Ned Lamont. “We are looking forward to a long and fruitful relationship with PMI and it is clear they are focused on maintaining a strong partnership with the State of Connecticut for the foreseeable future.”

The Connecticut location will offer employees a better range of commuting and living options following the paradigm shift caused by COVID-19. The headquarters will be aligned with PMI’s science- and technology-focused transformation, using state-of-the-art innovation to accommodate remote work and ensure that employees have an inspiring and comfortable workplace.

“We are excited that our new location will offer employees and their families a wide range of living options, from the suburbs of Fairfield County to the rural areas of Litchfield County, while also having the advantages of easy access to the New York metropolitan area. More encouraging are the pioneering and community-minded populace, an excellent school system and healthcare facilities, and ample recreational and green space,” said Charles Bendotti, Senior Vice President of People and Culture at PMI.

PMI will take possession on March 1, 2022, with the goal of having the office operational by mid-to-late summer 2022.

PMI is widely recognized as a top employer and a leader in gender equity, equitable pay, and environmental, social, and corporate governance (ESG) measures. Recognitions include:

- The first international company to achieve global EQUAL-SALARY certification

- Included in the 2021 Bloomberg Gender-Equality Index

- Certified Global Top Employer for five consecutive years by the Top Employers Institute

- Ranked on CDP’s A List for climate change for seven years in a row

- Included in the Dow Jones Sustainability Index North America

- Awarded CDP’s “triple A” score in 2020 for efforts to combat climate change and the protection of forests and water security

Since 2016, PMI has undergone a major business transformation, moving away from cigarettes and other combustible tobacco products in favor of smoke-free alternatives that, while not risk-free, are scientifically substantiated to be a better choice than continued smoking. PMI is committed to a smoke-free future, and its noncombustible products already accounted for nearly 30% of net revenues in the third quarter of 2021. Building on this progress, the company has accelerated its ambitions, now aiming to be a majority smoke-free company in terms of net revenues by the end of 2025.

The potential public health impact of PMI’s scientifically substantiated smoke-free products is increasingly being recognized by governments and public health authorities. For instance, in the U.S., the Food and Drug Administration (FDA) has issued marketing authorizations for IQOS, PMI’s electronically heated tobacco system. In July 2020, the FDA authorized the IQOS 2.4 system as a Modified Risk Tobacco Product (MRTP), concluding that issuing exposure modification orders for the system is “appropriate to promote the public health” and is “expected to benefit the health of the population as a whole.” The agency is now conducting a scientific review of the company’s MRTP application for the IQOS 3 system, which was authorized for sale in the U.S. in December 2020.

Globally, as of September 30, 2021, an estimated 14.9 million adults have switched to IQOS and stopped smoking.

Note to editor:

In the U.S., Altria Group, Inc. has a license to market IQOS.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders, and other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, versions of PMI’s IQOS Platform 1 device and consumables have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn products, nicotine-containing vapor products, and oral nicotine products. As of September 30, 2021, PMI’s smoke-free products are available for sale in 70 markets in key cities or nationwide, and PMI estimates that approximately 14.9 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit and

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

NEW YORK--( / )--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group”), a MS-ONLINE ENLOTTO biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces further positive data from its current investigational new 강일동맞고 오피걸스 drug (IND)-enabling studies for ALS-4, a small drug molecule candidate indicated for the treatment of infections caused by Staphylococcus aureus (or “S. aureus”), including methicillin-resistant Staphylococcus aureus (MRSA, one of the “super-bugs”), based on a novel anti-virulence non-bactericidal approach. Subject to completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in second half of 2020 and commence a phase 1 trial in North America.

ALS-4 is a small molecule which inhibits 강일동맞고 AVWOW dehydrosqualene desaturase of S. aureus (incl. MRSA), an enzyme that is critically involved in the biosynthesis MS-ONLINE of staphyloxanthin, a commonly visible “golden pigment” covering the bacteria. Staphyloxanthin is believed to be primarily responsible for the bacteria’s defense mechanism against the attack from reactive oxygen species (ROS) deployed by phagocytic cells and neutrophils.[1]

Through inhibiting the production of staphyloxanthin, we believe that ALS-4 renders S. aureus highly susceptible to the host’s immune defense (see below for in vivo data and experimental outline). This novel mechanism MS-ONLINE 7MM is significantly different from the bactericidal approach found in currently marketed antibiotics used to treat S. aureus, which are experiencing increasing drug resistance issues[2]. Specifically, MRSA 강일동맞고 infections in humans typically exhibit high rates of morbidity and mortality and can cause MS-ONLINE 조이로또 metastatic or complicated 자브넷 Throughsuch as infective endocarditis or sepsis, with MS-ONLINE relapse and hospital readmission after S. aureus bacteremia common and costly[3].

Based on our testing in a rat bacteremia survival model, a lethal (10^9 CFU) dose of MRSA (USA300-LAC) was introduced through the tail vein. ALS-4 was administered orally at 10mg/kg per animal 30 minutes after the infection for twice a day thereafter (N=9). A control untreated group was given a sterile vehicle solution (N=9). Survival was monitored for 7 days. 0 out of 9 animals (0%) in the control untreated group survived past day 4, in contrast, 5 out of 9 animals (56%) treated with ALS-4 survived past day 7, which is determined to be statistically significant compared with the control group MS-ONLINE 헨타이러브TV (p=0.013).

In addition we conducted a study in a non-lethal rat bacteremia infection model. The animals were challenged with a non-lethal (107 CFU) dose of MRSA (USA300-LAC) through 인연 Intail vein. In order to simulate a more realistic clinical scenario, treatment was introduced 14-days after the model induction, where ALS-4 was administered orally twice a MS-ONLINE 엠팍 day at 10mg/kg per animal (N=8). A control untreated group was given a sterile vehicle solution (N=8). After 7 days of ALS-4 treatment, the kidneys were collected and the bacterial titers were measured. Remarkably, ALS-4 reduced the organ bacterial load by 99.5%, from 63,096±18 CFU/g 강일동맞고 아라공유 in the control group to 316±49 CFU/g in the ALS-4 treated group, which is determined to be statistically significant (p=0.01).

Last but not least, MS-ONLINE 먹튀라인 ALS-4 has successfully inhibited staphyloxanthin production in 11 strains of S. aureus. These include 5 strains of Methicillin-sensitive S. aureus (MSSA): SH1000, HG003, USA300-JE2, Newman, and ATCC29213 with an IC50 of 70.5±6nM, 54.4±4nM, 37.7±4nM, 23.7±1nM, and 30.02±5nM respectively; 5 strains of Methicillin-resistant S. aureus (MRSA): USA300, USA300-3, USA300-LAC, ST239III, 인연 LastCOL, with MS-ONLINE 김소장버스 an IC50 of 30.8±5nM, 42.8±6nM, 43.6±5nM, 16.3±8nM, and 0.9±1nM respectively; and 1 strain of vancomycin-intermediate S. aureus (VISA), Mu3 with an IC50 of 2.6±1nM.

Based on our testing, we believe ALS-4 increases the susceptibility of S. aureus including MRSA to oxidative damage MS-ONLINE 복권사업 by inhibiting production of staphyloxanthin,. In a hydrogen peroxide killing assay, after the addition of 1.5% H2O2, ALS-4 demonstrated an additional reduction MS-ONLINE of bacterial CFU by 93.5%, from 61,600±6437 CFU/ml 인연 Basedthe untreated group to 4,000±230 CFU/ml in the ALS-4 treated group, which is determined to be statistically significant (p=0.003).

With respect to the study carried out to investigate the capability of ALS-4 to induce antibiotic resistance in S. aureus after prolonged exposure, USA300-LAC was 즉석복권판매 Within 3 different conditions for 10 days. For the treatment group 1 μM of ALS-4 was added; for the positive control group 0.12 μg/mL of clindamycin and 16 μg/mL of erythromycin was added from MS-ONLINE 연합복권 day 1 to day 4, after which clindamycin was withdrawn. For the negative control group, dimethyl sulfoxide (DMSO) was added. On day 11, the bacteria were harvested and then cultured for 16 hr for the determination of the MIC of clindamycin. The prolonged exposure to ALS-4 or DMSO does not affect the MIC value of clindamycin (0.12 μg/mL); while the prolonged exposure to clindamycin + erythromycin triggers antibiotics resistance rapidly with the MIC increased from 0.12 μg/mL MS-ONLINE 전자복권 to greater than 5 μg/mL.

Based on our study we believe ALS-4 is unlikely to be prone to drug resistance since it is non-bactericidal. Growth inhibition studies were performed MS-ONLINE FREESEX on different strains of S. aureus and other bacteria, including 3 strains of MSSA (ATCC29212, SH1000 and HG003), 1 strain of MRSA (USA300), 1 strain of VISA (ATCC700698 Mu3), as well as 6 different bacteria (E. coli, A. baumannii, S. cerevisiae, B. subtilis, E. faecalis, and K. pneumoniae). In all of the tested strains of bacteria, no growth inhibition effect was MS-ONLINE PJ observed at the highest tested concentration 소나기티비공. BasedALS-4 (250uM). Therefore ALS-4 does not appear to have any direct bacteriostatic or bactericidal activity against many species of bacteria, thus greatly reducing the selection pressure for drug resistance to emerge.

We also assessed the MS-ONLINE bjt potential impact on the efficacy of vancomycin, the mainstay of treatment for infections caused by MRSA, when used in conjunction with ALS-4. 8 different strains of S. aureus (USA300 MS-ONLINE 로또볼색 FPR3757, USA300-3, USA300-LAC, USA300-JE2, Mu3, HG003, ATCC29213 and clinical isolate ST239III) were used in this study. Our data showed that no effect on the MIC of vancomycin was observed when the concentration of ALS-4 was below 25 μM. Therefore, we believe that ALS-4 does not interfere with the action of vancomycin.

In addition, MS-ONLINE 섹스마스터 compared with the current mainstay of treatment for S. aureus infections such as vancomycin or daptomycin which is typically administered in an IV injectable form (with MS-ONLINE 야동볼수있는곳 the exception of an oral form vancomycin specifically for treatment of Clostridium difficile diarrhea and staphylococcal enterocolitis only), an oral MS-ONLINE active agent enables wider market penetration targeting 강일동맞고 야한싸이트 both outpatient as well as potential prophylactic markets.

GLP Toxicity 중국야한영화 GLPMS-ONLINE 야동동영상

ALS-4 is currently undergoing IND-enabling studies and has so MS-ONLINE 섹스영화 far shown positive 야한놈 ALS-4profiles. As elucidated in our previous press release MS-ONLINE 섹스사진 dated September 9, 2019, ALS-4 did not show any mutagenicity in the in vitro 강일동맞고 즉석복권 Ames tests. Our currently generated in vitro micronucleus test results also showed that ALS-4 is not genotoxic, indicating the non-mutagenic nature of the drug. Furthermore, the results of the in vitro hERG assay study predicts a low risk MS-ONLINE 로또1등방법 of ALS-4 causing cardiac QT prolongation.

For further general MS-ONLINE 로또1등예상번호 presentation, 강일동맞고 please visit: MS-ONLINE 섹시

For further technical MS-ONLINE presentation, MS-ONLINE 성인망가 강일동맞고 성인망가 please 텀블러야동검색 For

About MS-ONLINE 로또4등상금 Aptorum MS-ONLINE 야동추천 텀블러야동검색 AboutLimited

Aptorum Group Limited (Nasdaq: APM) is MS-ONLINE 로또복권당첨확률 강일동맞고 로또복권당첨확률 a pharmaceutical company dedicated to developing and commercializing novel therapeutics to 텀블러야동검색 Aptorumunmet medical needs. Aptorum MS-ONLINE 로또무료번호받기 Group is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases and other disease areas.

For more information about Aptorum Group, MS-ONLINE please visit MS-ONLINE 야한이야기

Disclaimer and MS-ONLINE Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the MS-ONLINE 로또당첨번호전체 Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” MS-ONLINE 페티쉬코리아 “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and MS-ONLINE 69TV projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

[1] WINWIN [1]2017 MS-ONLINE 로또번호맞추기 8(5): e01224-17 MS-ONLINE 로또추첨게임

[2] Microbiol MS-ONLINE 야외섹스 Spectr. 2019 Mar;7(2) MS-ONLINE 비비디

[3] Clin Infect Dis. 2019 Nov 27;69(12):2112-2118Korea MS-ONLINE Newswire distributes your news across every MS-ONLINE 넷마블 media 전화방/퇴폐이용원/안마등 [3]MS-ONLINE 즉석복권스피또 through 강일동맞고 NLOTTO the industry’s largest press release distribution network